Whole Exome Sequencing

Whole Exome Sequencing

Lab method: Next generation sequencing

Price / TAT: Solo sample 1567 EUR / 15 weeks
Trio sample 3100 EUR / 15 weeks

Specimen requirements: 2-4 ml of blood with anticoagulant EDTA

4 µg DNA in TE, AE or pure sterile water at 100-250 ng/µl
The A260/A280 ratio should be 1.8-2.0. DNA sample should be run on an agarose gel as a single band, showing no degradation, alongside with a quantitative DNA marker.


Ordering information: Go to online ordering or download sample submission form

Indications for genetic testing:

1. Confirmation of clinical diagnosis
2. Diagnosing of genetically and phenotypically heterogeneous group of disorders
3. Testing patients with atypical phenotype
4. Diagnosis of patients with genetic disorders for which diagnostic panels are not available
5. Genetic counseling

Whole exome sequencing (WES) includes the sequencing of the protein coding regions and their flanking intronic regions in ~20,000 genes of the human genome. The coding region represents 1-2% of the human genome but contains approximately 85% of disease-causing mutations. WES is performed on the HiSeq sequencer, Illumina Inc with the following characteristics: 70-100x average coverage, 214,405 target exons.

Trio exome sequencing of family members, usually affected child with parents is highly recommended for faster and more precise identifying of disease-causing mutation and determining the pattern of inheritance. In addition to patient’s phenotype/disease associated variants, incidental findings are reported according to ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.

Exome sequencing can be an efficient tool for clinicians to confirm patients’ diagnosis of complicated conditions not covered by conventional testing approaches.

Genetic testing services

Genetic testing at Asper Biogene

Genetic testing services offered by Asper Biogene comply with the highest level quality standards and are certified by Clinical Laboratory Improvement Amendments (CLIA) and ISO 15189:2012. We regularly participate in external quality assurance schemes to maintain the highest level of testing services.

Single mutation analysis

Single mutation analysis for any familial or known mutation.

Single gene sequencing

Sequencing of the entire coding region of any single gene.

Targeted regions sequencing

Targeted regions sequencing includes the analysis of selected hotspot regions in disease associated genes.

Deletion/duplication analysis

Deletion/duplication analysis for the genes listed in our test menu.

Next generation sequencing (NGS) panels

Our testing menu includes a wide variety of carefully constructed NGS panels. Essential medical specialities are covered by our clinically relevant, validated, and up-to-date gene panels. NGS panels include the sequencing of entire coding regions plus flanking intronic regions. Likely pathogenic or pathogenic variants are confirmed by Sanger sequencing.

We upgrade the existing gene panels continuously as well as create additional ones based on new scientific knowledge and customer requests. 

Customized NGS panels

In addition to ready-to-use tests, we develop and implement custom-made tests and solutions to meet our customers’ specific needs. 

Existing NGS panels are easily adjustable for your clinical practice and patients’ indications.

For customized NGS panels, fill in the Custom test order form or ask for more information on redesigning solutions for additional panels.

Whole exome sequencing (WES)

WES includes the sequencing of coding regions and their flanking intronic regions in approximately 20,000 genes of the human genome. The coding region represents 1–2% of the human genome but contains approximately 85% of the disease-causing mutations.

WES is an effective option to detect the rare causal variants of Mendelian disorders. Service can be useful for clinicians to diagnose affected patients with conditions that have eluded traditional diagnostic approaches.

Phenotype/diagnosis associated likely pathogenic or pathogenic variants are confirmed by Sanger sequencing.

Whole genome sequencing (WGS)

WGS determines the complete DNA sequence of an individual’s genome, including chromosomal DNA and mitochondrial DNA.

WGS covers the sequencing of the entire coding and non-coding regions of the genome. WGS enables detection of non-coding sequence variants that could be informative in diagnosing genetically and phenotypically heterogeneous or undiagnosed diseases. WGS can reveal the full range of variations, including single nucleotide variations, copy number variations, changes in transposable elements, and structural variations.

Phenotype/diagnosis associated likely pathogenic or pathogenic variants are confirmed by Sanger sequencing.

Trio exome or genome sequencing of family members (usually affected child with parents) is highly recommended for faster and more precise identifying of disease-causing mutations and determining the inheritance pattern. In addition to the patient’s phenotype/disease associated variants, incidental findings are reported according to  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.

Bioinformatic analysis and interpretation of customer’s genetic data

Asper Biogene’s qualified geneticists analyze and interpret your sequencing data, deletion/duplication analysis results etc.

Ask for a customized solution from our experienced team to facilitate your clinical practice.

Results report

Our results report contains detailed information on the detected variants, including bioinformatics analysis, biological interpretation, comprehensive clinical interpretation and recommendations for follow-up analyses. Rare and known pathogenic variants are assessed and classified according to the standards and guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Confirmation of likely pathogenic or pathogenic variants is performed by Sanger sequencing.